Chemotherapy News and Research

Latest Chemotherapy News and Research

Combination of chemotherapy and radiation improves control of cancer within bladder

Adding chemotherapy to radiation therapy for muscle invasive bladder cancer allows 67 percent of people to be free of disease in their bladders two years after treatment. This compares to 54 percent of people who receive radiation alone, according to the largest randomized study of its kind presented at the plenary session, November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

26 Oct 2010

UMC of Göttingen purchases BSD-500 Hyperthermia System

BSD Medical Corporation announced today that the University Medical Center (UMC) of Göttingen, Germany, has purchased a BSD-500 Hyperthermia System (BSD-500). UMC was established in 1732 and is a center of scientific excellence in Europe and the most prominent medical center in Lower Saxony, Germany.

25 Oct 2010

Seattle Genetics, Millennium to feature SGN-35 in three poster presentations at ISHL symposium

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced that brentuximab vedotin (SGN-35) will be featured in three poster presentations at the 8th International Symposium on Hodgkin Lymphoma (ISHL) being held October 23-26, 2010 in Cologne, Germany.

25 Oct 2010

Soligenix reports Phase 2 clinical trial results of orBec for GVHD

Soligenix, Inc. a late-stage biopharmaceutical company, today reported preliminary results from its Phase 2 "proof-of-concept" exploratory clinical trial of orBec for the prevention of acute Graft-versus-Host disease (GVHD) in patients undergoing myeloablative conditioning regimens with initiation of dosing prior to hematopoietic cell transplantation (HCT) and continuing through the post-transplantation period.

25 Oct 2010

Antigenics expands HSPPC-96 Phase 2 clinical study in glioma

Antigenics, Inc. today announced the expansion of a phase 2 clinical study of HSPPC-96 (Oncophage® vaccine; vitespen), Antigenics' personalized therapeutic cancer vaccine, in patients with newly diagnosed glioma.

25 Oct 2010

Researchers publish effects of doctor-designed formula against breast cancer

Researchers at Indiana University and Methodist Research Institute have published the dramatic effects of a natural formula against breast cancer. The impressive results are found in the most recent publication of Integrative Cancer Therapies.

25 Oct 2010

Fred Hutchinson Center offers research-based tip sheets for breast cancer survivors

Throughout October, National Breast Cancer Awareness Month, experts from Fred Hutchinson Cancer Research Center and its clinical care partner, the Seattle Cancer Care Alliance, are offering weekly research-based tip sheets regarding breast cancer prevention, screening and early detection, treatment and survivorship.

25 Oct 2010

Childhood cancer survivors at increased risk of gastrointestinal problems

People treated for cancer when they were children have a higher-than-average risk of gastrointestinal problems - some mild, some quite severe - in the years following treatment, according to a study to be presented at the 42nd Congress of the International Society of Paediatric Oncology (SIOP) in Boston on Sunday, Oct. 24.

25 Oct 2010

Bright Starts announces 2010 Pink Power Mom winners

In an ongoing effort to support breast cancer awareness, education and research, Bright Starts announces the winners of its fourth annual Pink Power Mom search. The winners are eight inspirational mothers who have survived (or are currently battling) breast cancer and have used their experience to make a profound difference in the lives of other women affected by the disease

22 Oct 2010

Myrexis to present Phase 2 monotherapy study results of Azixa in patients with GBM

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present at the 2010 Society for Neuro-Oncology Scientific Meeting and Education Day, to be held November 18-21, 2010 in Montreal, Canada.

22 Oct 2010

Advaxis completes patient recruitment in ADXS11-001 phase II study for cervical dysplasia

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, completes recruitment of the first group of patients in its US cervical dysplasia (CIN) phase II study of ADXS11-001 as required for the planned DMSB (safety board) meeting scheduled to be held January 11, 2011.

22 Oct 2010

New data from ESHO/EORTC STBSG Phase III clinical study of hyperthermia

BSD Medical Corporation announced publication in Internal Medicine News Digital Network of new data from the ESHO/EORTC Soft Tissue and Bone Sarcoma Group (STBSG) Phase III clinical study of hyperthermia.

21 Oct 2010

Matrix-Bio's VeraMarker-BCR blood test predicts breast cancer recurrence 13 months before clinical diagnosis

Connie Krabbe understands the fear and foreboding breast cancer survivors feel when visiting their physicians for post-treatment check-ups. Two of her four sisters died of metastatic cancer related to breast cancer, enduring bone, brain, and ovarian cancer before succumbing to the disease in their early 50s.

21 Oct 2010

Effects of breast cancer do not end after chemotherapy

For some women, the effects of breast cancer, the most common cancer affecting women, do not end when they leave the hospital. Now, researchers in the University of Missouri School of Health Professions have studied the lives of breast cancer patients following chemotherapy and found that their environments and available support systems help determine the quality of their lives.

21 Oct 2010

Researchers suggest 'watch and wait' strategy for girls with germ-cell ovarian tumors

Researchers from Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) have found that as many as 50 percent of young girls treated for germ-cell ovarian tumors might safely be spared chemotherapy using a "watch and wait" strategy to determine if the follow-up treatment is needed.

21 Oct 2010

Partnership between institutions in high- and low-resource areas can improve pediatric sarcoma treatment

Raising the survival rate of children with sarcoma in low-income countries will require steps to diagnose the disease sooner, train cancer pathologists, expand radiation therapy services, create multi-specialty teams to review each case, and other actions, according to an international study led by Dana-Farber/Children's Hospital Cancer Center researchers. The findings will be presented at the 42nd Congress of the International Society of Paediatric Oncology (SIOP) in Boston on Friday, Oct. 22.

21 Oct 2010

Unitedhealth says it will test lump sum payments for some cancer care, reports earnings

Health insurer UnitedHealth said Tuesday that it will test a new way payment method for cancer doctors. The program pays doctors a lump sum payment for providing care during an entire course of care for the disease instead of how it's done now with a fee for each service a doctor provides.

21 Oct 2010

NYU Langone Medical Center announces establishment of Smilow Comprehensive Prostate Cancer Center

NYU Langone Medical Center is pleased to announce that it has established The Smilow Comprehensive Prostate Cancer Center with a $5 million gift from Joel E. Smilow, a member of the Board of Trustees at NYU Langone Medical Center and New York University. The Smilow Center is dedicated to providing comprehensive, state-of-the-art personalized care for men with prostate cancer as well as educating men and their families about the disease and the wide range of treatment options available today.

21 Oct 2010

A new way to pay for chemotherapy

Kaiser Health News staff writer Julie Appleby reports: "One of the nation's largest health insurers said today it is testing a new way to pay for some cancer treatments, aiming to identify the best medicines - and limit profits doctors make by dispensing in-office chemotherapy drugs" (Appleby, 10/20).

21 Oct 2010

Genzyme reports results of Clolar combination Phase 3 trial in adult AML

Genzyme Corporation announced results today from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy agent cytarabine (ara-c) to cytarabine plus placebo in relapsed-refractory adult acute myeloid leukemia (AML).

21 Oct 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

Combination of chemotherapy and radiation improves control of cancer within bladder

UMC of Göttingen purchases BSD-500 Hyperthermia System

Seattle Genetics, Millennium to feature SGN-35 in three poster presentations at ISHL symposium

Soligenix reports Phase 2 clinical trial results of orBec for GVHD

Antigenics expands HSPPC-96 Phase 2 clinical study in glioma

Researchers publish effects of doctor-designed formula against breast cancer

Fred Hutchinson Center offers research-based tip sheets for breast cancer survivors

Childhood cancer survivors at increased risk of gastrointestinal problems

Bright Starts announces 2010 Pink Power Mom winners

Myrexis to present Phase 2 monotherapy study results of Azixa in patients with GBM

Advaxis completes patient recruitment in ADXS11-001 phase II study for cervical dysplasia

New data from ESHO/EORTC STBSG Phase III clinical study of hyperthermia

Matrix-Bio's VeraMarker-BCR blood test predicts breast cancer recurrence 13 months before clinical diagnosis

Effects of breast cancer do not end after chemotherapy

Researchers suggest 'watch and wait' strategy for girls with germ-cell ovarian tumors

Partnership between institutions in high- and low-resource areas can improve pediatric sarcoma treatment

Unitedhealth says it will test lump sum payments for some cancer care, reports earnings

NYU Langone Medical Center announces establishment of Smilow Comprehensive Prostate Cancer Center

A new way to pay for chemotherapy

Genzyme reports results of Clolar combination Phase 3 trial in adult AML

Cancer Research - Second Edition eBook

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Newsletters you may be interested in